Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect of Dulaglutide on Major Cardiovascular Events in Patients With Type 2 Diabetes: Researching Cardiovascular Events With a Weekly INcretin in Diabetes (REWIND)

NCT01394952 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01394952
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01394952 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect of Dulaglutide on Major Cardiovascular Events in Patients With Type 2 Diabetes: Researching Cardiovascular Events With a Weekly INcretin in Diabetes (REWIND)
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
July 22, 2011
Completion date
August 21, 2018
Enrollment
9,901 (actual)
Sites
300

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular disease, diabetes mellitus, type 2